Skip to content

Evaluation of Intestinal Parasites in Patients With Intestinal Cancer in Sohag, Egypt.

Evaluation of Intestinal Parasites in Patients With Intestinal Cancer in Sohag, Egypt.

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05850884
Enrollment
100
Registered
2023-05-09
Start date
2023-11-30
Completion date
2024-05-30
Last updated
2023-11-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Intestinal Parasites in Patients With Intestinal Cancer

Brief summary

This study aims to evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals

Detailed description

Intestinal parasitic infections continue to be characterized as a significant cause of morbidity worldwide, and according to World Health Organization (WHO) statistics, more than a quarter of the world's population, mostly in developing countries, are infected Acquisition of infection, clinical severity, and outcome of a parasitic disease depend on innate and acquired host immunity as well as on the parasite's response against the host when the infection is established Chronic infections and inflammation along with unhealthy diet, stressful lifestyle, cell damage, constant exposure to radiation, and harmful chemicals are risk factors for the development of cancers As infectious factors, the Blastocystis hominis and Cryptosporidium spp. are opportunistic protozoa isolated from the human host gastrointestinal tract, These prevalent enteric parasites may cause serious challenges in people undergoing colorectal cancer treatment (chemotherapy)

Interventions

DIAGNOSTIC_TESTstool examination

Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis

Sponsors

Sohag University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
OTHER

Eligibility

Sex/Gender
ALL
Age
2 Years to No maximum

Inclusion criteria

* intestinal cancer patients (colorectal cancer, intestinal lymphoma, gastrointestinal stromal tumors, and other malignant variants)

Exclusion criteria

* patient took antibiotics within the previous four weeks and anti-parasitic drugs within the previous two weeks

Design outcomes

Primary

MeasureTime frameDescription
evaluate the intestinal parasitic infections in patients with intestinal cancer in comparison to non-cancer individuals12 months• Each collected sample will be divided into three parts; 1st part will be examined freshly without preservatives by macroscopic and microscopic examination, the 2nd part will be preserved for concentration techniques, staining, and microscopic examination and the 3rd part will be cultivated for Strongyloides stercoralis diagnosis

Countries

Egypt

Contacts

Primary Contactnagwa i seleem, dominstrator
nagwaibrahim@med.sohag.edu.eg01060289117

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026